The head of the New York Biotechnology Association, Nathan Tinker, is in the throes of developing a marketing strategy as part of his goal of attracting new biotech companies to join the group in a field he considers critical to the state’s economic future.Mr. Tinker, who was named executive director of the trade group six months after Karin Duncker left the post to join a law firm, has his work cut out for him, according to Dr. Mark Monane, manager of equity research at Needham and Co., who cites the state’s high cost of doing business.>>> Discuss This Story
